Telix and ITM merge in $1.65B deal poised to expand radiopharmaceutical development and manufacturing
Telix Pharmaceuticals and ITM Isotope Technologies Munich have agreed to a merger valued at approximately $1.65 billion, the companies announced Monday.
The deal will bring together a large-scale radioisotope manufacturing operation and a commercial radiopharmaceutical development platform. Telix and ITM say their partnership is intended to integrate each company’s capabilities into a single organization, giving them greater control over the path from isotope production to patient treatment.
Under the agreement, Australia-based Telix will acquire 100% of ITM's shares for $1.65 billion upfront on a cash-free, debt-free basis, subject to shareholder and regulatory approvals. The transaction includes $1.25 billion in Telix shares to be issued to ITM sellers, $302 million in net debt to be assumed by Telix and $96 million in management equity rollover.
Telix also could pay up to an additional $700 million in contingent consideration tied to regulatory approvals and sales milestones for ITM-11 (lutetium-177 edotreotide), a somatostatin receptor-targeted therapy being investigated for gastroenteropancreatic neuroendocrine tumors (GEP NETs). ITM-11 has completed the Phase 3 COMPETE trial and a second Phase 3 study, COMPOSE, is fully enrolled, with an interim analysis expected in the first half of 2027. If approved, the therapy would give Telix an additional late-stage therapeutic asset in the neuroendocrine tumor market.
The companies say the combined organization would have a commercial distribution network spanning more than 65 countries and a therapeutic pipeline covering multiple disease areas. This comes as demand for radioisotopes and therapeutic radiopharmaceuticals expands, increasing the importance of reliable isotope production and distribution alongside the development of new therapies.
“This merger positions Telix at the forefront of the consolidation that is occurring as the industry matures. ITM is the leader in radioisotope production, with deep scientific expertise and a track record of value-adding innovation. We have enjoyed a close working relationship with ITM for many years and there is strong management alignment for the rationale behind this transaction,” Christian Behrenbruch, PhD, Telix's managing director and group CEO, said in an announcement on the merger. “By combining our complementary strengths, we will create a company with commercial scale, world-leading supply and the most exciting theranostic drug portfolio in the sector.”
If the transaction closes as planned, existing Telix shareholders would own approximately 76.3% of the combined company, while ITM shareholders would hold approximately 23.7%. The deal is expected to close by the end of 2026.
Read more here.
In addition to her background in journalism, Hannah also has patient-facing experience in clinical settings, having spent more than 12 years working as a registered rad tech. She began covering the medical imaging industry for Innovate Healthcare in 2021.